The Philippines Radiotherapy Market, estimated at USD 24.6 Mn in 2025, is expected to exhibit a CAGR of 5.7% and reach USD 36.3 Mn by 2032.
The industry is witnessing significant growth driven by rising demand for advanced, reliable, and cost-effective medical devices across diagnostic, therapeutic, and monitoring applications. Rapid advancements in device design, digital health integration, and adoption of minimally invasive technologies are reshaping the competitive landscape. Furthermore, supportive regulatory frameworks, increasing healthcare investments, and the growing focus on patient-centric care are expected to create new growth avenues for market players.
The growing geriatric population is the major driving factor for the market development over the forecast period. Aging populations often experience a higher incidence of cancer. As the population ages, the demand for cancer treatment, including radiotherapy, is likely to increase. According to an article published on August 29, 2025, by the Phillipine Information Agency, the official public information arm of the Government of the Republic of the Philippines, the Commission on Population and Development projects that in 2035, 14% of the population will be senior citizens, up from 8.5% in 2025. Furthermore, the Philippine Statistics Authority (PSA) reported that the number of Filipinos aged 60 and up has more than doubled to 9.22 Mn in 2025, up from 4.6 Mn in 2000.
Philippines Radiotherapy Market - Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2025, as "coronavirus disease 2025" or COVID-19. This virus spreads quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
The COVID-19 pandemic led to disruptions in routine healthcare services, including cancer screenings and treatments. Elective procedures, including some cancer treatments, were delayed or rescheduled to prioritize resources for COVID-19 patients. According to an article published in 2025 by Acta Medica Philippina, an open-access health science journal, the Philippines, like other countries, was compelled to redirect the majority of its health resources to the COVID-19 pandemic when Enhanced Community Quarantine (ECQ) was announced on March 16, 2025. Except for health care personnel and the military, everyone was confined to their houses under ECQ. To cope up with pandemic, all institutions followed global guidelines, such as infection control measures, telemedicine, and changes to radiotherapy programs. Despite this, most institutions experienced greater treatment interruptions during ECQ. The percentage of patients who had interruptions was likewise significantly higher during the ECQ (66.37%) than during the pre-COVID month (30.56%). To conclude, the COVID-19 pandemic negatively affected the market growth.